Abstract
BackgroundEarly diagnosis and therapy of papillary thyroid carcinoma (PTC) is essential for reducing recurrence and improving the long-term survival. In this study, we aimed to investigate the proteome profile of plasma and screen unique proteins which could be used as a biomarker for predicting PTC.MethodsSerum samples were collected from 29 PTC patients and 29 nodular goiter (NG) patients. Five PTC serum samples and five NG serum samples were selected for proteome profiles by proteomics. Eight proteins in PTC and NG serum samples were selected for confirmation by enzyme-linked immunosorbent assay analysis. Receiver operating characteristic curves was used to evaluate the diagnostic value of potential biomarkers.ResultsComplement C4-A (C4A) and plasminogen (PLG) were significantly lower in serum samples of PTC patients compared with NG patients. C4A was observed to have excellent diagnostic accuracy for PTC, with a sensitivity of 91.67% and specificity of 83.33%. The diagnostic value of PLG for PTC was demonstrated by a sensitivity at 87.50% and specificity at 75.00%. The AUC for C4A and PLG was 0.97 ± 0.02 and 0.89 ± 0.05.ConclusionC4A and PLG appeared to be excellent potential biomarkers for the prediction of PTC.
Highlights
Thyroid carcinoma is the most common endocrine malignancy with increasing incidences worldwide [1]
Through screening assay using proteomics and enzyme-linked immunosorbent assay analysis (ELISA), we successfully identified that serum C4A and plasminogen (PLG) were proteins that met these requirements
Twenty-nine Papillary thyroid carcinoma (PTC) patients included 27 patients diagnosed as primary thyroid malignancy and two as suspicious for malignancy according to cytology result of fine-needle aspiration biopsy (FNAB)
Summary
Thyroid carcinoma is the most common endocrine malignancy with increasing incidences worldwide [1]. Epidemiologic studies have shown that thyroid cancer is responsible for 567,233 new cases and 41,071 deaths in 2018 worldwide [2]. Papillary thyroid carcinoma (PTC) comprises more than 80% of thyroid cancer. Cervical lymph node metastases and aggressive subset are related to the risk of recurrence or death [4, 5]. And accurate diagnosis of PTC is essential for prevention of progression and recurrence. Diagnosis and therapy of papillary thyroid carcinoma (PTC) is essential for reducing recurrence and improving the long-term survival.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
